These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 23656755)
1. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation. Cetinkaya C; Martinsson T; Sandgren J; Träger C; Kogner P; Dumanski J; Díaz de Ståhl T; Hedborg F BMC Cancer; 2013 May; 13():231. PubMed ID: 23656755 [TBL] [Abstract][Full Text] [Related]
2. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Spitz R; Hero B; Ernestus K; Berthold F Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740 [TBL] [Abstract][Full Text] [Related]
3. Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion. Villamón E; Berbegall AP; Piqueras M; Tadeo I; Castel V; Djos A; Martinsson T; Navarro S; Noguera R PLoS One; 2013; 8(1):e53740. PubMed ID: 23341988 [TBL] [Abstract][Full Text] [Related]
4. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma. Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568 [TBL] [Abstract][Full Text] [Related]
5. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors. Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945 [TBL] [Abstract][Full Text] [Related]
6. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255 [TBL] [Abstract][Full Text] [Related]
7. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Carén H; Kryh H; Nethander M; Sjöberg RM; Träger C; Nilsson S; Abrahamsson J; Kogner P; Martinsson T Proc Natl Acad Sci U S A; 2010 Mar; 107(9):4323-8. PubMed ID: 20145112 [TBL] [Abstract][Full Text] [Related]
8. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q. Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200 [TBL] [Abstract][Full Text] [Related]
9. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890 [TBL] [Abstract][Full Text] [Related]
10. The Detection of Genetic Parameters for Prognostic Stratification of Neuroblastoma Using Multiplex Ligation-Dependent Probe Amplification Technique. Tumer S; Altungoz O; Bagci O; Olgun HN Genet Test Mol Biomarkers; 2016 Feb; 20(2):74-80. PubMed ID: 26790040 [TBL] [Abstract][Full Text] [Related]
11. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Schleiermacher G; Mosseri V; London WB; Maris JM; Brodeur GM; Attiyeh E; Haber M; Khan J; Nakagawara A; Speleman F; Noguera R; Tonini GP; Fischer M; Ambros I; Monclair T; Matthay KK; Ambros P; Cohn SL; Pearson AD Br J Cancer; 2012 Oct; 107(8):1418-22. PubMed ID: 22976801 [TBL] [Abstract][Full Text] [Related]
12. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744 [TBL] [Abstract][Full Text] [Related]
13. Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy. Passariello A; De Brasi D; Defferrari R; Genesio R; Tufano M; Mazzocco K; Capasso M; Migliorati R; Martinsson T; Siani P; Nitsch L; Tonini GP Eur J Med Genet; 2013 Nov; 56(11):626-34. PubMed ID: 24035971 [TBL] [Abstract][Full Text] [Related]
14. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Spitz R; Hero B; Simon T; Berthold F Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759 [TBL] [Abstract][Full Text] [Related]
15. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable Ambros IM; Tonini GP; Pötschger U; Gross N; Mosseri V; Beiske K; Berbegall AP; Bénard J; Bown N; Caron H; Combaret V; Couturier J; Defferrari R; Delattre O; Jeison M; Kogner P; Lunec J; Marques B; Martinsson T; Mazzocco K; Noguera R; Schleiermacher G; Valent A; Van Roy N; Villamon E; Janousek D; Pribill I; Glogova E; Attiyeh EF; Hogarty MD; Monclair TF; Holmes K; Valteau-Couanet D; Castel V; Tweddle DA; Park JR; Cohn S; Ladenstein R; Beck-Popovic M; De Bernardi B; Michon J; Pearson ADJ; Ambros PF J Clin Oncol; 2020 Nov; 38(31):3685-3697. PubMed ID: 32903140 [TBL] [Abstract][Full Text] [Related]
16. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028 [TBL] [Abstract][Full Text] [Related]
17. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Fix A; Lucchesi C; Ribeiro A; Lequin D; Pierron G; Schleiermacher G; Delattre O; Janoueix-Lerosey I Genes Chromosomes Cancer; 2008 Oct; 47(10):819-34. PubMed ID: 18553563 [TBL] [Abstract][Full Text] [Related]
18. Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma. Fransson S; Östensson M; Djos A; Javanmardi N; Kogner P; Martinsson T Int J Oncol; 2016 Mar; 48(3):1103-16. PubMed ID: 26794043 [TBL] [Abstract][Full Text] [Related]
19. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Spitz R; Hero B; Ernestus K; Berthold F Clin Cancer Res; 2003 Jan; 9(1):52-8. PubMed ID: 12538451 [TBL] [Abstract][Full Text] [Related]
20. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Plantaz D; Vandesompele J; Van Roy N; Lastowska M; Bown N; Combaret V; Favrot MC; Delattre O; Michon J; Bénard J; Hartmann O; Nicholson JC; Ross FM; Brinkschmidt C; Laureys G; Caron H; Matthay KK; Feuerstein BG; Speleman F Int J Cancer; 2001 Mar; 91(5):680-6. PubMed ID: 11267980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]